|
|
More than 150,000 Americans killed by cardiovascular disease are younger than the age of 65 years.
For pediatric patients, intravenous fluids are the most commonly cited products involved in medication errors that are reported to the USP.
Inotropic therapy does not have a role in the treatment of most heart failure patients. These drugs can make patients feel and function better but usually do not lengthen the predicted length of their lives.
Persons who overdose with cardiac glycosides have a better chance of overall survival if they can survive the first 24 hours after the overdose.
All adverse reactions are commonly charted in red ink in the patient's record and usually are noted on the front of the chart. Failure to follow correct documentation procedures may result in malpractice lawsuits.